ClinicalTrials.gg
CompletedNCT02348606OSAUpdated Jul 23, 2019Results posted

"Twelve-week Study of the Safety and Efficacy of JZP-110 in the Treatment of Excessive Sleepiness in OSA"

A Phase 3 interventional study of JZP-110 and Placebo oral tablet in Obstructive Sleep Apnea, sponsored by Jazz Pharmaceuticals. Completed at 59 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-23.

Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
476
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 753 studies in Sleep Apnea, Obstructive with a site in United States — 126 open to participants now, 160 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.

Enrollment
31st of 594
476 · median 49
Started
2015
with 42 others
Phase 3
39 of 753
6 open now
Registered
290th of 753
by date

Among the 753 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 31st largest by enrollment of the 594 interventional ones that give a count, is one of 43 that started in 2015, is one of 39 in phase 3, and was the 290th registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

126 of the 753 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 753 studies in Sleep Apnea, Obstructive with a site in United States, or all of them as a file.
02

Study summary

This trial is a 12 week, randomized, double-blind, placebo controlled, multicenter, 5-arm parallel group study of safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with OSA.

03

Conditions studied

  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  1. Male or female between 18 and 75 years of age, inclusive
  2. Diagnosis of OSA according to ICSD-3 criteria
  3. from 18 to \<45 kg/m2
  4. Consent to use a medically acceptable method of
  5. Willing and able to provide written

Major Exclusion Criteria:

  1. Female subjects who are pregnant, nursing, or lactating
  2. Any other medical, behavioral, or psychiatric disorder other than OSA that is associated with excessive sleepiness
  3. History or presence of bipolar disorder, bipolar related disorders, schizophrenia, schizophrenia spectrum disorders, or other psychotic disorders according to criteria
  4. History or presence of any acutely unstable medical condition, behavioral or psychiatric disorder (including active suicidal ideation), or surgical history that could affect the safety of the subject or interfere with study efficacy, safety, PK assessments, or the ability of the subject to complete the trial per the judgment of the Investigator.
  5. History of bariatric surgery within the past year or a history of any gastric bypass procedure
  6. Presence or history of significant cardiovascular disease
  7. Use of any over-the-counter (OTC) or prescription medications that could affect the evaluation of excessive sleepiness
  8. Received an drug in the past 30 days or five half-lives
  9. Previous exposure to or participation in a clinical trial of JZP-110 (ADX-N05, R228060, or YKP10A)
  10. History of phenylketonuria (PKU) or history of to phenylalanine-derived products
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
476 participants (actual)

Study arms

  • Active comparator
    37.5 mg of JZP-110

    Once Daily Dosing

    Drug: JZP-110

  • Active comparator
    75 mg of JZP-110

    Once Daily Dosing

    Drug: JZP-110

  • Active comparator
    150 mg of JZP-110

    Once Daily Dosing

    Drug: JZP-110

  • Active comparator
    300 mg of JZP-110

    Once Daily Dosing

    Drug: JZP-110

  • Active comparator
    Placebo

    Once Daily Dosing

    Drug: Placebo oral tablet

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12

    Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12.

    Time frame: Baseline to Week 12

  2. Change in ESS Score From Baseline to Week 12

    Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12

    Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since start of treatment on a 7-point scale ranging from 1 = very much improved to 7 = very much worse. This is the key secondary endpoint.

    Time frame: 12 Weeks

  2. Change in Sleep Latency Time on Each of the 5 MWT Trials at Week 12

    Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at week 12.

    Time frame: Baseline and Week 12

  3. Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-minute MWT From Baseline to Week 4

    Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to week 4.

    Time frame: Baseline to Week 4

  4. Change in ESS Score From Baseline to Week 1, Week 4, and Week 8

    Change in Epworth Sleepiness Scale (ESS) score from Baseline to Weeks 1, 4, and 8. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.

    Time frame: Baseline to Weeks 1, 4, and 8

  5. Percentage of Subjects Reported as Improved on the PGIc at Week 1, Week 4, and Week 8

    Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 1, Week 4, and Week 8. PGIc was rated by subjects and measures the change in their condition since treatment start on a 7-point scale ranging from 1 = very much improved to 7 = very much worse.

    Time frame: Weeks 1, 4, and 8

  6. Percentage of Subjects Reported as Improved on the Clinical Global Impression of Change (CGIc) at Week 12

    Percentage of subjects reported as improved (minimally, much, or very much) on the CGIc at Week 12. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.

    Time frame: Week 12

  7. Percentage of Subjects Reported as Improved on the CGIc at Week 1, Week 4, and Week 8

    Percentage of subjects reported as improved (minimally, much, or very much) on the CGIc at Week 1, Week 4, and Week 8. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.

    Time frame: Weeks 1, 4, and 8

07

Results

Posted Jul 23, 2019

Participant flow

Note: 476 subjects were enrolled and randomized, however 2 subjects never received drug. This resulted in 474 subjects comprising the safety population.

Participant flow — Overall Study
Milestone37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Started5862117118119
Completed495410694101
Not completed98112418

Outcome measures

PrimaryChange in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12

Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to Week 12.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · minutes
Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 12
minutes37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Change in Maintenance of Wakefulness Test (MWT) From Baseline to Week 124.74 ± 1.4189.08 ± 1.35810.96 ± 0.97312.99 ± 1.0380.21 ± 0.997
PrimaryChange in ESS Score From Baseline to Week 12

Change in Epworth Sleepiness Scale (ESS) score from Baseline to Week 12. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · points on a scale
Change in ESS Score From Baseline to Week 12
points on a scale37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Change in ESS Score From Baseline to Week 12-5.1 ± 0.64-5.0 ± 0.62-7.7 ± 0.44-7.9 ± 0.46-3.3 ± 0.45
SecondarySubjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12

Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 12. PGIc was rated by subjects and measures the change in their condition since start of treatment on a 7-point scale ranging from 1 = very much improved to 7 = very much worse. This is the key secondary endpoint.

Time frame:
12 Weeks
Reported as:
Number · percentage of subjects
Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 12
percentage of subjects37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Subjects Reported Improved on the Patient Global Impression of Change (PGIc) at Week 1255.472.489.788.749.1
SecondaryChange in Sleep Latency Time on Each of the 5 MWT Trials at Week 12

Time course of efficacy in MWT: Change in sleep latency (in minutes) on each of the 5 MWT trials at week 12.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · minutes
Change in Sleep Latency Time on Each of the 5 MWT Trials at Week 12
minutes37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Trial 13.03 ± 1.8815.77 ± 1.80810.87 ± 1.28412.48 ± 1.401-0.40 ± 1.327
Trial 26.93 ± 1.9289.47 ± 1.84911.91 ± 1.33214.94 ± 1.425-0.44 ± 1.380
Trial 33.59 ± 1.83711.32 ± 1.75111.50 ± 1.26110.90 ± 1.3400.58 ± 1.294
Trial 46.11 ± 1.8459.04 ± 1.7948.93 ± 1.27211.94 ± 1.3591.29 ± 1.305
Trial 53.57 ± 1.9527.75 ± 1.8398.05 ± 1.3477.59 ± 1.4320.18 ± 1.361
SecondaryChange in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-minute MWT From Baseline to Week 4

Change in mean sleep latency time (in minutes) as determined from the first 4 trials of a 40-minute MWT from baseline to week 4.

Time frame:
Baseline to Week 4
Reported as:
Least squares mean · minutes
Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-minute MWT From Baseline to Week 4
minutes37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Change in the Mean Sleep Latency Time as Determined From the First 4 Trials of a 40-minute MWT From Baseline to Week 44.53 ± 1.3607.20 ± 1.30711.69 ± 0.93213.77 ± 0.9761.24 ± 0.942
SecondaryChange in ESS Score From Baseline to Week 1, Week 4, and Week 8

Change in Epworth Sleepiness Scale (ESS) score from Baseline to Weeks 1, 4, and 8. A negative change from baseline represents improvement in excessive sleepiness. The ESS is a self-administered questionnaire with 8 questions. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness. An analysis of covariance (ANCOVA) was used for the analysis of ESS scores. The response variable was the change in ESS score from baseline.

Time frame:
Baseline to Weeks 1, 4, and 8
Reported as:
Least squares mean · points on a scale
Change in ESS Score From Baseline to Week 1, Week 4, and Week 8
points on a scale37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Week 1-4.5 ± 0.66-4.4 ± 0.65-5.5 ± 0.46-6.6 ± 0.46-2.6 ± 0.47
Week 4-4.7 ± 0.65-4.8 ± 0.63-6.1 ± 0.45-6.6 ± 0.46-2.9 ± 0.45
Week 8-4.7 ± 0.70-6.3 ± 0.67-6.9 ± 0.48-7.7 ± 0.50-3.8 ± 0.49
SecondaryPercentage of Subjects Reported as Improved on the PGIc at Week 1, Week 4, and Week 8

Percentage of subjects reported as improved (minimally, much, or very much) on the PGIc at Week 1, Week 4, and Week 8. PGIc was rated by subjects and measures the change in their condition since treatment start on a 7-point scale ranging from 1 = very much improved to 7 = very much worse.

Time frame:
Weeks 1, 4, and 8
Reported as:
Number · percentage of subjects
Percentage of Subjects Reported as Improved on the PGIc at Week 1, Week 4, and Week 8
percentage of subjects37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Week 158.965.578.382.547.4
Week 460.777.684.584.353.5
Week 857.179.388.887.857.0
SecondaryPercentage of Subjects Reported as Improved on the Clinical Global Impression of Change (CGIc) at Week 12

Percentage of subjects reported as improved (minimally, much, or very much) on the CGIc at Week 12. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.

Time frame:
Week 12
Reported as:
Number · percentage of subjects
Percentage of Subjects Reported as Improved on the Clinical Global Impression of Change (CGIc) at Week 12
percentage of subjects37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Percentage of Subjects Reported as Improved on the Clinical Global Impression of Change (CGIc) at Week 1258.970.790.588.749.1
SecondaryPercentage of Subjects Reported as Improved on the CGIc at Week 1, Week 4, and Week 8

Percentage of subjects reported as improved (minimally, much, or very much) on the CGIc at Week 1, Week 4, and Week 8. CGIc was rated by clinicians and measures the change in the subject's condition since treatment starts on a 7-point scale ranging from 1= very much improved to 7= very much worse.

Time frame:
Weeks 1, 4, and 8
Reported as:
Number · percentage of subjects
Percentage of Subjects Reported as Improved on the CGIc at Week 1, Week 4, and Week 8
percentage of subjects37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Week 162.560.375.782.646.5
Week 460.777.685.281.752.6
Week 855.474.187.887.849.1

Adverse events

Collected over Through Week 14. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
37.5 mg of JZP-1100/58 (0%)2/58 (3.4%)17/58 (29.3%)
75 mg of JZP-1100/62 (0%)0/62 (0%)21/62 (33.9%)
150 mg of JZP-1100/117 (0%)1/117 (0.9%)41/117 (35%)
300 mg of JZP-1100/118 (0%)0/118 (0%)60/118 (50.8%)
Placebo0/119 (0%)2/110 (1.8%)30/119 (25.2%)
Most frequent serious events
Most frequent serious events
Event37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
Bile duct obstructionHepatobiliary disorders1/580/620/1170/1180/110
Streptococcal endocarditisInfections and infestations1/580/620/1170/1180/110
Road traffic accidentInjury, poisoning and procedural complications0/580/620/1170/1181/110
SciaticaNervous system disorders0/580/620/1170/1181/110
Back painMusculoskeletal and connective tissue disorders0/580/620/1170/1181/110
GoitreEndocrine disorders0/580/620/1170/1181/110
HyperglycaemiaMetabolism and nutrition disorders0/580/621/1170/1180/110
Most frequent other events
Showing 10 of 12
Most frequent other events
Event37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110Placebo
HeadacheNervous system disorders4/585/6210/11717/11810/119
AnxietyPsychiatric disorders1/582/626/11716/1180/119
Decreased appetiteMetabolism and nutrition disorders1/583/629/11714/1181/119
NauseaGastrointestinal disorders3/583/6210/11712/1187/119
InsomniaPsychiatric disorders1/580/623/11711/1182/119
Dry mouthGastrointestinal disorders1/581/625/1179/1182/119
DiarrhoeaGastrointestinal disorders1/583/625/1178/1181/119
NasopharyngitisMetabolism and nutrition disorders2/581/627/1178/1188/119
SinusitisMetabolism and nutrition disorders1/584/620/1173/1183/119
Feeling jitteryGeneral disorders3/583/621/1177/1180/119

Baseline characteristics

Age, Continuous
Age, Continuous(years)37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110PlaceboTotal
Mean57.1 ± 10.1954.4 ± 11.4652.7 ± 10.5753.2 ± 10.6254.1 ± 11.4153.9 ± 10.75
Sex: Female, Male
Sex: Female, Male(Participants)37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110PlaceboTotal
Female1927454442177
Male3935727477297
Race (NIH/OMB)
Race (NIH/OMB)(Participants)37.5 mg of JZP-11075 mg of JZP-110150 mg of JZP-110300 mg of JZP-110PlaceboTotal
American Indian or Alaska Native000011
Asian3136417
Native Hawaiian or Other Pacific Islander001012
Black or African American101418212689
White4546939087361
More than one race012104
Unknown or Not Reported000000
08

Study locations

59 sites
  • Pulmonary Associates
    Glendale, Arizona 85306, United States
  • Mayo Clinic in Arizona
    Scottsdale, Arizona 85259, United States
  • Preferred Research Partners
    Little Rock, Arkansas 72211, United States
  • UC San Diego Medical Center
    La Jolla, California 92037, United States
  • So Cal Institute For Respiratory Diseases, Inc.
    Los Angeles, California 90048, United States
  • Pacific Sleep Medicine
    Oceanside, California 92054, United States
  • Stanford University Center for Narcolepsy
    Redwood City, California 94063, United States
  • Pacific Research Network, Inc.
    San Diego, California 92103, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Clinical Research Group of St. Petersburg
    Saint Petersburg, Florida 33707, United States
  • Florida Pediatric Research Institute
    Winter Park, Florida 32789, United States
  • NeuroTrials Research Inc.
    Atlanta, Georgia 30342, United States
  • SleepMed of Central Georgia
    Macon, Georgia 31201, United States
  • Northwestern University Feinberg School of Medicine
    Chicago, Illinois 60611, United States
  • University of Illinois at Chicago College of Nursing
    Chicago, Illinois 60612, United States
  • Kentucky Research Group
    Louisville, Kentucky 40218, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21224, United States
  • The Center for Sleep & Wake Disorders
    Chevy Chase, Maryland 20815, United States
  • Neurocare, Inc.
    Newton, Massachusetts 24590, United States
  • Henry Ford Hospital Sleep Disorders & Research Center
    Detroit, Michigan 48202, United States
  • Clinical Neurophysiology Services
    Sterling Heights, Michigan 48314, United States
  • Minnesota Lung Center
    Edina, Minnesota 55435, United States
  • Sleep Medicine & Research Center, St. Luke's Hospital
    Chesterfield, Missouri 63017, United States
  • University of Missouri
    Columbia, Missouri 65201, United States
  • Clayton Sleep Institute
    Saint Louis, Missouri 63143, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Clinilabs
    New York, New York 10019, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • Hickory Research Center
    Hickory, North Carolina 28602, United States
  • Hickory Research Center, ARSM Research, LLC
    Huntersville, North Carolina 28078, United States
  • Raleigh Neurology Associates
    Raleigh, North Carolina 27607, United States
  • Northcoast Clinical Trials Inc.
    Beachwood, Ohio 44122, United States
  • Sleep Management Institute
    Cincinnati, Ohio 45245, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45255, United States
  • Case Western Reserve University
    Cleveland, Ohio 44106, United States
  • Southwest Cleveland Sleep Research Center
    Cleveland, Ohio 44130, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Ohio Sleep Medicine & Neuroscience Institute
    Dublin, Ohio 43017, United States
  • Mercy St. Anne & Mercy St. Charles Sleep Disorders Center
    Toledo, Ohio 43606, United States
  • Sleep Med of South Carolina
    Columbia, South Carolina 29201, United States
  • FutureSearch Trials of Neurology LP
    Austin, Texas 78731, United States
  • Todd J. Swick
    Houston, Texas 77063, United States
  • Sleep Therapy & Research Center
    San Antonio, Texas 78229, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • London Health Sciences Centre
    London, Ontario N6A 5W9, Canada
  • Niagra Clinical Research
    Niagra Falls, Ontario L2E 7H9, Canada
  • Toronto Sleep Institute
    Toronto, Ontario M4P 1P2, Canada
  • Toronto Psychiatric Research Foundation
    Toronto, Ontario M5K 2A7, Canada
  • Pediatric Sleep Research Inc.
    Toronto, Ontario M6J 3S3, Canada
  • Hospital Roger Salengro
    Lille, 59000, France
  • Universite Paris 5 Hôtel-Dieu
    Paris, 75004, France
  • Hopital Bichat - Claude Bernard
    Paris, 75018, France
  • medbo Bezirksklinikum Regensburg Schlafmedizinisches Zentrum
    Regensburg, Bayern 93053, Germany
  • Universitätsklinikum Münster Department für Neurologie
    Muenster, North Rhine-Westphalia 48149, Germany
  • Advanced Sleep Research GmbH
    Berlin, 10117, Germany
  • Studienzentrum Wilhelmshoehe
    Kassel, 34131, Germany
  • Somni bene GmbH Institut für Medizinische Forschung und Schlafmedizin Schwerin GmbH
    Schwerin, 19053, Germany
  • Sleep Wake Center SEIN Heemstede
    Heemsteded, Noord Holland 2103 SW, Netherlands
09

References and documents

Publications

  • Rosenberg R, Thorpy MJ, Dauvilliers Y, Schweitzer PK, Zammit G, Gotfried M, Bujanover S, Scheckner B, Malhotra A. Incidence and duration of common early-onset adverse events in randomized controlled trials of solriamfetol for treatment of excessive daytime sleepiness in obstructive sleep apnea and narcolepsy. J Clin Sleep Med. 2022 Jan 1;18(1):235-244. doi: 10.5664/jcsm.9550. PubMed 34283019 ↗
  • Schweitzer PK, Mayer G, Rosenberg R, Malhotra A, Zammit GK, Gotfried M, Chandler P, Baladi M, Strohl KP. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment. Chest. 2021 Jul;160(1):307-318. doi: 10.1016/j.chest.2021.02.033. Epub 2021 Feb 22. PubMed 33631141 ↗
  • Weaver TE, Menno DM, Bron M, Crosby RD, Morris S, Mathias SD. Determination of thresholds for minimally important difference and clinically important response on the functional outcomes of sleep questionnaire short version in adults with narcolepsy or obstructive sleep apnea. Sleep Breath. 2021 Sep;25(3):1707-1715. doi: 10.1007/s11325-020-02270-3. Epub 2021 Jan 4. PubMed 33394323 ↗
  • Rosenberg R, Baladi M, Bron M. Clinically relevant effects of solriamfetol on excessive daytime sleepiness: a posthoc analysis of the magnitude of change in clinical trials in adults with narcolepsy or obstructive sleep apnea. J Clin Sleep Med. 2021 Apr 1;17(4):711-717. doi: 10.5664/jcsm.9006. Erratum In: J Clin Sleep Med. 2021 Nov 1;17(11):2343. doi: 10.5664/jcsm.9596. PubMed 33226332 ↗
  • Weaver TE, Drake CL, Benes H, Stern T, Maynard J, Thein SG, Andry JM Sr, Hudson JD, Chen D, Carter LP, Bron M, Lee L, Black J, Bogan RK. Effects of Solriamfetol on Quality-of-Life Measures from a 12-Week Phase 3 Randomized Controlled Trial. Ann Am Thorac Soc. 2020 Aug;17(8):998-1007. doi: 10.1513/AnnalsATS.202002-136OC. PubMed 32353246 ↗
  • Schweitzer PK, Rosenberg R, Zammit GK, Gotfried M, Chen D, Carter LP, Wang H, Lu Y, Black J, Malhotra A, Strohl KP; TONES 3 Study Investigators. Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. Am J Respir Crit Care Med. 2019 Jun 1;199(11):1421-1431. doi: 10.1164/rccm.201806-1100OC. PubMed 30521757 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Dec 2016 and a completion of Dec 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2019, 2 years 7 months after primary completion. A results delay was requested in Nov 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2015
First posted
Jan 28, 2015
Start
May 2015
Primary completionActual
Dec 2016
CompletionActual
Dec 2016
Results delay requested
Nov 16, 2017
Results first posted
Jul 23, 2019
Last update
Jul 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02348606
Responsible party
Sponsor
First posted
Jan 28, 2015
Start date
May 2015
Primary completion
Dec 2016
Completion
Dec 2016
Results posted
Jul 23, 2019
Last update
Jul 23, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solriamfetol

Start the discussion